By Tony Fong

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies has started a Series C financing round targeting $10 million to further its regulatory submissions and for marketing activities, its CEO said today.

The company disclosed in a Form D filed this week with the US Securities and Exchange Commission that it had raised $1.9 million financing round. As a result, it has paid back a note held by six current shareholders in the firm, leaving Nuclea debt-free, CEO Patrick Muraca told GenomeWeb Daily News.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.